CN110734442A - 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof - Google Patents
3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof Download PDFInfo
- Publication number
- CN110734442A CN110734442A CN201911068625.0A CN201911068625A CN110734442A CN 110734442 A CN110734442 A CN 110734442A CN 201911068625 A CN201911068625 A CN 201911068625A CN 110734442 A CN110734442 A CN 110734442A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- methyl
- pyrazole
- indazole
- pyrazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to spiro [ indazole-pyrazoline with a pyrazole structure substituted by 3,4, 5-trimethoxyphenyl] kinds of 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline with pyrazole structure according to claim 1]The preparation method of the derivative is characterized by comprising the following steps of (1) synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazolecarboxaldehyde, (2) synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazol-1-yl) -4-pyrazolecarboxaldehyde hydrazone, (3) synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazol-1-yl) - α -chloro-4-pyrazolecarboxaldehyde hydrazone, (4) synthesis of 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1-phenylH-indazole-4 (5)H) -synthesis of ketones; (5) 3,4, 5-trimethoxyphenyl groupSpiro [ indazole-pyrazoline substituted with pyrazole structure]And (3) synthesizing a derivative.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to spiro [ indazole-pyrazoline ] derivatives with pyrazole structures substituted by 3,4, 5-trimethoxyphenyl, and a preparation method and application thereof.
Background
5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one, of the following chemical formula:
the 1, 3-dipolar cycloaddition reaction is the most important method for synthesizing five-membered heterocyclic compounds with good region and main body selectivity, and is also an active -type reaction in heterocyclic pharmaceutical chemistry research, triazole has aromaticity and abundant electrons in a molecular structure, can interact with enzymes and receptors in organisms by forming hydrogen bonds, and has various biological activities.
In order to better research the influence of aggregation of different heterocycles in the same molecule on pharmacological activity, spiro [ indazole-pyrazoline ] derivatives containing a pyrazole structure and substituted by 3,4, 5-trimethoxyphenyl are synthesized through 1, 3-dipolar cycloaddition reaction.
Disclosure of Invention
The invention aims to provide spiro [ indazole-pyrazoline ] derivatives containing pyrazole structures and substituted by 3,4, 5-trimethoxyphenyl and a preparation method thereof, and spiro [ indazole-pyrazoline ] derivatives containing pyrazole structures and substituted by 3,4, 5-trimethoxyphenyl are prepared.
In order to achieve the purpose, the technical scheme of the invention is as follows:
spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure and substituted by 3,4, 5-trimethoxyphenyl have the following chemical structural formula:
wherein: ar is 3,4,5- (CH)3O)3C6H2-。
A process for preparing 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure according to claim 1, comprising the steps of:
(1) synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazolecarboxaldehyde (compound 1): dissolving 21mmol of 1,2, 4-triazole in 50mL of ethanol solvent, adding 25mmol of potassium hydroxide, performing ultrasound at normal temperature of 25 ℃ for half an hour, performing rotary evaporation on ethanol under reduced pressure, adding 40mL of DMSO, adding 15mmol of 5-chloro-1-phenyl-3-methyl-4-formylpyrazole in batches, performing ultrasonic treatment at 50 ℃ for 2 hours, pouring the mixture into 200mL of ice water after TLC detection is finished, precipitating light yellow solid, and performing suction filtration; drying the solid matter, and recrystallizing with ethanol-water to obtain a compound 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazole formaldehyde (compound 1);
(2) synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone (compound 2): adding 22mmol of phenylhydrazine into a flask containing 10mL of tetrahydrofuran, refluxing and stirring in a boiling water bath until the phenylhydrazine is dissolved, slowly dropwise adding 20mL of anhydrous ethanol solution in which 20mmol of 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazole formaldehyde (compound 1) is dissolved, continuing refluxing and stirring in the boiling water bath for 1h, and dropwise adding 10 drops of concentrated hydrochloric acid until a light yellow precipitate appears; refluxing and stirring in a continuous boiling water bath for 5 hours, stopping the water bath, adding 20mL of distilled water, stirring, deepening the color of a light yellow precipitate, and performing suction filtration to obtain a yellowish red needle-shaped product; washing with anhydrous ether for several times, and vacuum drying to obtain 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone (compound 2);
(3) synthesizing 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde hydrazone (compound 3), namely adding 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone (compound 2) into 50ml of 1, 2-dichloroethane and 30ml of isopropanol, magnetically stirring to completely dissolve the 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone, then adding tert-butyl hypochlorite into a salt bath at the temperature of-12 ℃, vigorously stirring for 2 hours, during the period, controlling the temperature to be below-5 ℃ to obtain a light blue transparent liquid, transferring the product into a round-bottom flask, evaporating the solvent at the temperature of 50 ℃ under reduced pressure to obtain a light yellow oily substance, adding a small amount of petroleum ether, heating to dissolve the mixture, separating out a large amount of yellow solid, and carrying out suction filtration under reduced pressure to obtain 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde hydrazone (compound;
(4) synthesis of 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (compound 4): dissolving 10mmol of 1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one and 10mmol of 3,4, 5-trimethoxybenzaldehyde in 10mL of ethanol, adding 2mL of 40% aqueous NaOH solution, stirring at 80 ℃ for 3 hours, filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product, namely 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (a compound 4);
(5) adding 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (compound 4) and 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde hydrazone (compound 3) into 20mL of ethanol, dropwise adding a mixed solution of 0.5mL of pyridine and 10mL of ethanol into the solution by using a constant-pressure dropping funnel, continuously stirring at normal temperature for 2 hours after the dropwise adding is finished, tracking the reaction by TLC, filtering after the reaction is finished, concentrating the filtrate under reduced pressure, performing silica gel column chromatography, and using ethyl acetate and petroleum ether as eluent to obtain a final product.
The mass ratio of the 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone (compound 2) to the tert-butyl hypochlorite substance is 5: 8.
The ratio of the amount of the 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde oxime (compound 3) to the amount of the 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (compound 4) is 3: 2.
V in the eluent(Ethyl acetate):V(Petroleum ether)＝1:8。
The 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing a pyrazole structure is applied to antitumor drugs.
The spiro [ indazole-pyrazoline ] derivatives containing a pyrazole structure and 3,4, 5-trimethoxyphenyl substitution provided by the invention and a preparation method thereof are characterized in that isoxazole rings are introduced into a 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -one structure by using a 1, 3-dipolar cycloaddition method, so that spiro [ indazole-pyrazoline ] derivatives containing 5- (1-phenyl-3-methyl-4-1, 2, 4-triazolyl) structure pyrazole substitution are synthesized, the spiro [ indazole-pyrazoline ] derivatives containing 5- (1-phenyl-3-methyl-4-1, 2, 4-triazolyl) structure pyrazole substitution prepared by the invention have a strong tumor cell inhibition effect, and a foundation is provided for application in the field of medicines in steps.
Drawings
FIG. 1 is a flow chart of the preparation method of steps (1) to (3) in the preparation method of spiro [ indazole-pyrazoline ] derivatives containing pyrazole structures and substituted by 3,4, 5-trimethoxyphenyl groups according to the present invention;
FIG. 2 is a flow chart of a preparation method of step (4) in the preparation method of spiro [ indazole-pyrazoline ] derivatives containing pyrazole structures and substituted by 3,4, 5-trimethoxyphenyl;
FIG. 3 is a flow chart of a preparation method of step (5) in the preparation method of spiro [ indazole-pyrazoline ] derivatives containing pyrazole structures and substituted by 3,4, 5-trimethoxyphenyl groups according to the present invention;
Detailed Description
The following is a detailed description of the technical solution of the present invention with reference to the drawings and the following examples, which are not intended to limit the present invention.
In order to better research the influence of aggregation of different heterocycles in the same molecule on pharmacological activity, spiro [ indazole-pyrazoline ] derivatives containing a pyrazole structure and substituted by 3,4, 5-trimethoxyphenyl are synthesized through 1, 3-dipolar cycloaddition reaction.
The invention provides spiro [ indazole-pyrazoline ] derivatives containing pyrazole structures and substituted by 3,4, 5-trimethoxyphenyl, which have the following chemical structural formula:
wherein: ar is 3,4,5- (CH)3O)3C6H2-。
Example 1
(1) Synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazolecarboxaldehyde (compound 1): dissolving 21mmol of 1,2, 4-triazole in 50mL of ethanol solvent, adding 25mmol of potassium hydroxide, performing ultrasound at normal temperature of 25 ℃ for half an hour, performing rotary evaporation on ethanol under reduced pressure, adding 40mL of DMSO, adding 15mmol of 5-chloro-1-phenyl-3-methyl-4-formylpyrazole in batches, performing ultrasonic treatment at 50 ℃ for 2 hours, pouring the mixture into 200mL of ice water after TLC detection is finished, precipitating light yellow solid, and performing suction filtration. Drying the solid matter, and recrystallizing with ethanol-water to obtain the compound 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazole formaldehyde.
(2) Synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone (compound 2): 22mmol of phenylhydrazine is added into a flask containing 10mL of tetrahydrofuran, reflux and stirring are carried out in a boiling water bath until the phenylhydrazine is dissolved, then 20mL of absolute ethanol solution dissolved with 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazole formaldehyde (20 mmol) is slowly dripped, reflux and stirring are carried out in the boiling water bath for 1h, 10 drops of concentrated hydrochloric acid are dripped, and light yellow precipitate appears. And (4) refluxing and stirring in a continuous boiling water bath for 5 hours, stopping the water bath, adding 20mL of distilled water, stirring, deepening the color of the light yellow precipitate, and performing suction filtration to obtain a yellowish red needle-shaped product. Washing with anhydrous ether for several times, and vacuum drying to obtain 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone (compound 2).
(3) Synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazol-1-yl) - α -chloro-4-pyrazolecarboxaldehyde hydrazone (compound 3) Compound 2(10.0mmol) was added to 50ml of 1, 2-dichloroethane and 30ml of isopropanol, and completely dissolved by magnetic stirring, then 18ml (16g, 16mmol) of tert-butyl hypochlorite was added in three portions in a salt bath at-12 ℃ and vigorously stirred for 2 hours, during which time the temperature was carefully controlled below-5 ℃ to obtain a pale blue transparent liquid, the product was transferred to a round-bottomed flask, the solvent was evaporated under reduced pressure (50 ℃) to obtain a pale yellow oil, a small amount (m.p.: 60-90 ℃) of petroleum ether was added, and the mixture was heated to dissolve, and a large amount of yellow solid precipitated, and suction filtered under reduced pressure to obtain Compound 3.
(4) Synthesis of 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (compound 4): dissolving 10mmol of 1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -one and 10mmol of 3,4, 5-trimethoxybenzaldehyde in 10mL of ethanol, adding 2mL of 40% NaOH aqueous solution, stirring at 80 ℃ for 3 hours, filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing by using ethanol for purification, filtering and drying to obtain the product ketone.
(5) Adding 1mmol of compound 4(5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one) and 1.5mmol of compound 3 (1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazolecarboxaldehyde hydrazone) into 20mL of ethanol, dropwise adding a mixed solution of 0.5mL of pyridine and 10mL of ethanol into the solution by using a constant-pressure funnel, continuing stirring at normal temperature for 2 hours after the dropwise addition is finished, tracking the reaction by TLC, filtering after the reaction is finished, concentrating the filtrate under reduced pressure, carrying out silica gel column chromatography, and obtaining an eluent which is ethyl acetate/petroleum ether (60-90 ℃), 1/8(V/V), thereby obtaining compound 5.
The experimental data are as follows, kinds of 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure (compound 5) are light yellow powder, the yield is 76.2%, the melting point is 164-165 ℃, and the nuclear magnetic hydrogen spectrum data and the element analysis data are as follows:
1H NMR(CDCl3)δ:8.18(s,1H,N＝C-H),8.06(s,1H,triazole-H),7.98(s,1H,triazole-H),7.51-7.41(m,17H,Ar-H),6.47(s,1H),3.76(s,9H,-OCH3),3.13(t, J＝6.5Hz,2H),3.02(t,J＝6.5Hz,2H),2.55(s,3H,CH3).
IR(KBr)v/cm-13439(N-C＝O),3136(ArH),2983(CH3),1781(C＝O), 1615,1597,1465(C＝N,C＝C),
m/e:731(100.0％)
Anal.calcd.for C42H37N9O4：C,68.93；H,5.10；N,17.23found C,68.90；H,5.14；N,17.19。
in this example, MTT method is used to determine the in vitro inhibitory effect of compound 5 on different tumor strains, and the results of the determination of the antitumor activity of spiro [ indazole-pyrazoline ] derivatives containing 3,4, 5-trimethoxyphenyl substituted pyrazole structure are as follows:
The test compounds of different concentrations were coarse-screened in 96-well plates and IC was calculated from the resulting inhibition50Values, results are given in the table below.
TABLE 1 Compound 53,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] containing pyrazole structure]IC of derivatives on six tumor cell lines50Value of
In Table 1,3, 4, 5-trimethoxyphenyl-substituted spiro [ indazole-pyrazoline having pyrazole structure]IC of derivative (Compound 5) against six tumor cell lines50The values show that the compound has stronger tumor cell inhibition effect on A375 (melanoma cells), SW620 (human colorectal adenocarcinoma cells), A549 (lung adenocarcinoma cells), NCL-H460 (non-small cell lung cancer) and provide a foundation for -step application in the medical field.
Examples 2 to 5
Examples 2-5 the same as example 1 except that the amount ratio of 1-phenyl-3-methyl-5- (1,2, 4-triazol-1-yl) -4-pyrazolecarboxaldehyde hydrazone (compound 2) to the tert-butyl ester of hypochloride material in step (3) was varied, for comparison, table 2 was prepared:
TABLE 2
Examples 6 to 9
Examples 6-9 were otherwise the same as in example 1 except that in step (5), the ratio of the amounts of 1-phenyl-3-methyl-5- (1,2, 4-triazol-1-yl) - α -chloro-4-pyrazolecarboxaldehyde oxime (compound 3) to 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (compound 4) material was varied, for ease of comparison, to prepare tables 3:
TABLE 3
Examples 10 to 13
Examples 10-13 were otherwise identical to example 1 except that the addition of tert-butyl hypochlorite in step (3) was different (total amount added, and average addition), for comparison purposes, as shown in Table 4:
TABLE 4
| Number of additions | Yield of | |
| Example 1 | 3 | 92％ |
| Example 10 | 1 | 57％ |
| Example 11 | 2 | 85％ |
| Example 12 | 4 | 87％ |
| Example 13 | 5 | 84％ |
Examples 14 to 16
Examples 14-16 were otherwise identical to example 1 except that the temperature of the ice salt bath in step (3) was different and for ease of comparison, Table 5 was prepared:
TABLE 5
| Temperature of the Ice salt bath | Yield of | |
| Example 1 | -12 | 92％ |
| Example 14 | 0 | 0％ |
| Example 15 | -5 | 37％ |
| Example 16 | -8 | 66％ |
Comparative example 1
3,4, 5-trimethoxy substituted spiro [ indolizine-isoxazoline containing pyrazole structure prepared in example 1 of patent publication No. CN 108640929A]Derivatives, which were diluted in DMSO, tumor cells HepG2 (hepatoma cells), A375 (melanoma cells), SW620 (human colorectal adenocarcinoma cells), A549 (lung adenocarcinoma cells), NCL-H460 (non-small cell lung carcinoma), SKOV3 (ovarian cancer cells) were seeded in 4000/200. mu.L/well in 96-well plates, 2. mu.L of compound was added to each well to a final concentration of 12.0. mu.M, 6.0. mu.M, 3.0. mu.M, 1.5. mu.M, together at 37 ℃ with 5% CO2The cells were incubated in an incubator for 72 hours, with DMSO (1%) as a blank control. After 72 hoursAdding MTT with a final concentration of 0.25mg/mL, and standing at 37 deg.C with 5% CO2After 4 hours in the cell incubator, the solvent was blotted, 100. mu.l DMSO was added to each well, absorbance (OD value) was measured at 570nm with an enzyme-linked immunosorbent assay, and the data obtained was used to calculate IC50The value is obtained. Selecting compounds with high inhibitory activity, and determining the influence of different action times of the compounds at different concentrations on the human tumor cell cycle and apoptosis.
The test compounds of different concentrations were coarse-screened in 96-well plates and IC was calculated from the resulting inhibition50The values, results are given in table 6 below.
TABLE 63, 4, 5-trimethoxy substituted spiro [ indolizine-isoxazolines with pyrazole structure]IC of derivatives on six tumor cell lines50Value of
The above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and those skilled in the art can make various corresponding changes and modifications according to the present invention without departing from the spirit and the essence of the present invention, but these corresponding changes and modifications should fall within the protection scope of the appended claims.
Claims (6)
1, kinds of 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure, characterized in that, the chemical structural formula of the 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure is as follows:
wherein: ar is 3,4,5- (CH)3O)3C6H2-。
The process for preparing spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure substituted with 3,4, 5-trimethoxyphenyl group according to claim 1, comprising the steps of:
(1) synthesis of 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazolecarboxaldehyde: dissolving 21mmol of 1,2, 4-triazole in 50mL of ethanol solvent, adding 25mmol of potassium hydroxide, performing ultrasound at normal temperature of 25 ℃ for half an hour, performing rotary evaporation on ethanol under reduced pressure, adding 40mL of DMSO, adding 15mmol of 5-chloro-1-phenyl-3-methyl-4-formylpyrazole in batches, performing ultrasonic treatment at 50 ℃ for 2 hours, pouring the mixture into 200mL of ice water after TLC detection is finished, precipitating light yellow solid, and performing suction filtration; drying the solid matter, and recrystallizing with ethanol-water to obtain a compound 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazole formaldehyde;
(2) synthesizing 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone: adding 22mmol of phenylhydrazine into a flask containing 10mL of tetrahydrofuran, refluxing and stirring in a boiling water bath until the phenylhydrazine is dissolved, slowly dropwise adding 20mL of anhydrous ethanol solution in which 20mmol of 1-phenyl-3-methyl-5- (1,2, 4-triazolyl) -4-pyrazolecarboxaldehyde is dissolved, continuing refluxing and stirring in the boiling water bath for 1h, and dropwise adding 10 drops of concentrated hydrochloric acid until a light yellow precipitate appears; refluxing and stirring in a continuous boiling water bath for 5 hours, stopping the water bath, adding 20mL of distilled water, stirring, deepening the color of a light yellow precipitate, and performing suction filtration to obtain a yellowish red needle-shaped product; washing with anhydrous ether for many times, and vacuum drying to obtain 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone;
(3) synthesizing 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde hydrazone, namely adding 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone into 50ml of 1, 2-dichloroethane and 30ml of isopropanol, magnetically stirring to completely dissolve the 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone, then cooling to-12 ℃ in a salt bath, adding tert-butyl hypochlorite three times, vigorously stirring for 2h, during the period, controlling the temperature to be below-5 ℃ to obtain light blue transparent liquid, transferring the product into a round-bottom flask, evaporating the solvent to dryness at the temperature of 50 ℃ under reduced pressure to obtain light yellow oily matter, adding a small amount of petroleum ether, heating to mix, precipitating a large amount of yellow solid, and carrying out suction filtration under reduced pressure to obtain 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde hydrazone;
(4) synthesis of 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one: dissolving 1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one 10mmol and 3,4, 5-trimethoxybenzaldehyde 10mL in ethanol, adding 2mL of 40% NaOH aqueous solution, stirring at 80 ℃ for 3 hours, filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one;
(5) adding 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one and 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) - α -chloro-4-pyrazole formaldehyde hydrazone into 20mL of ethanol, dropwise adding a mixed solution of 0.5mL of pyridine and 10mL of ethanol into the solution by using a constant-pressure dropping funnel, continuously stirring at normal temperature for 2 hours after the dropwise adding is finished, tracking the reaction by TLC, filtering after the reaction is completed, concentrating the filtrate under reduced pressure, carrying out silica gel column chromatography, and eluting ethyl acetate and petroleum ether to obtain a final product.
3. The method for producing a3, 4, 5-trimethoxyphenyl-substituted spiro [ indazole-pyrazoline ] derivative having a pyrazole structure according to claim 2, wherein: the mass ratio of the 1-phenyl-3-methyl-5- (1,2, 4-triazole-1-yl) -4-pyrazole formaldehyde hydrazone to the tert-butyl hypochlorite substance in the step (3) is 5: 8.
4. The method for preparing 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure according to claim 2, wherein the ratio of the amount of 1-phenyl-3-methyl-5- (1,2, 4-triazol-1-yl) - α -chloro-4-pyrazolecarboxaldehyde oxime to the amount of 5- (3,4, 5-trimethoxybenzyl) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one compound in step (4) is 3: 2.
5. The 3,4, 5-trimethoxyphenyl-substituted spiro [ indazole-pyrazoline ] containing pyrazole structure according to claim 2]A process for the preparation of derivatives, characterized in that: v in eluent in the step (5)(Ethyl acetate):V(Petroleum ether)＝1:8。
6, kinds of 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivatives containing pyrazole structure according to claim 1, for use in antitumor drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911068625.0A CN110734442B (en) | 2019-11-05 | 2019-11-05 | 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911068625.0A CN110734442B (en) | 2019-11-05 | 2019-11-05 | 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110734442A true CN110734442A (en) | 2020-01-31 |
| CN110734442B CN110734442B (en) | 2021-03-09 |
Family
ID=69272201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911068625.0A Active CN110734442B (en) | 2019-11-05 | 2019-11-05 | 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110734442B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108752365A (en) * | 2018-06-14 | 2018-11-06 | 绍兴文理学院 | A kind of spiral shell [- isoxazoline of indolizine] derivative and the preparation method and application thereof containing pyrrazole structure |
-
2019
- 2019-11-05 CN CN201911068625.0A patent/CN110734442B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108752365A (en) * | 2018-06-14 | 2018-11-06 | 绍兴文理学院 | A kind of spiral shell [- isoxazoline of indolizine] derivative and the preparation method and application thereof containing pyrrazole structure |
Non-Patent Citations (1)
| Title |
|---|
| REN, DEMIN，等: "1,3-Dipolar cycloaddition of diphenylnitrilimine and 5-arylmethylidene-1-phenyl-1,5,6,7-tetrahydro-4H-indazol-4-ones to afford novel spiro[indazole-5,3"-pyrazole] derivatives", 《CHEMISTRY OF HETEROCYCLIC COMPOUNDS》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110734442B (en) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109053731B (en) | P-chloro-substituted pyridazinone-structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof | |
| CN108570086B (en) | Maleimide derivatives of the triazole structure containing arabinose and the preparation method and application thereof | |
| CN110642864B (en) | Spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110128444B (en) | P-nitrophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110759920A (en) | P-methoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110734442B (en) | 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof | |
| CN110746431B (en) | P-methylmercapto phenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110655522B (en) | O-chlorophenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110790769B (en) | P-methylphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110724148B (en) | P-chlorophenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN108623604B (en) | D-phenylalanine substituted maleimide derivative and preparation method and application thereof | |
| CN110183467B (en) | P-methoxyphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN112062799B (en) | Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
| CN110759921A (en) | Spiro [ indazole-pyrazoline ] derivative with p-fluorophenyl substituted pyrazole structure and preparation method and application thereof | |
| CN112645957A (en) | Pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | |
| CN109232570B (en) | Pyridazinone structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof | |
| CN108623603B (en) | L-leucine substituted maleimide derivative and preparation method and application thereof | |
| CN109180675B (en) | P-methoxy substituted pyridazinone structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof | |
| CN108690028B (en) | L-valine substituted maleimide derivative and preparation method and application thereof | |
| CN108707153B (en) | D-valine substituted maleimide derivative and preparation method and application thereof | |
| CN108676008B (en) | D-leucine substituted maleimide derivative and preparation method and application thereof | |
| CN108727383B (en) | L-phenylalanine substituted maleimide derivative and preparation method and application thereof | |
| CN110143971B (en) | Methylthiophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN109232572B (en) | P-methyl-substituted pyridazinone-structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof | |
| CN110128445B (en) | P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211117 Address after: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee after: Jinan Weiyang Technology Co.,Ltd. Address before: 312000 No. 508 West Ring Road, Zhejiang, Shaoxing Patentee before: SHAOXING University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211210 Address after: 100071 10a04-01, No. 4, Fufeng Road, Science Park, Fengtai District, Beijing Patentee after: BEIJING BOYA UNITED PHARMCEUFICAL INSTITUTE CO.,LTD. Address before: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee before: Jinan Weiyang Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |